End-to-end solutions for mRNA development and manufacturing

Vaccine Insights 2022; 1(4), 279;

DOI: 10.18609/vac/2022.039

Published: 21 November 2022
Susana Domingues-Vallon

Watch the video or read the poster to learn about:

  • Common challenges in the development and commercialization of mRNA therapeutic products  
  • The advantage of choice – why filling only your unique gaps can be the key to speed 
  • Summary of key foundational analytical and characterization capabilities  

Susana Domingues-Vallon is currently Thermo Fisher Scientific’s Global Subject Matter Expert for mRNA. With a PhD in Quantitative Biology from the University of Texas and a Business Management certification and Licentiate in Biology from the University of Algarve, Portugal, Susana has 13 years of expertise in TALEN’s, CRISPR/Cas9, and RNAi-related technologies. Prior to joining Thermo Fisher Scientific, Susana was a Key Account Manager at Roche Diagnostics, where she worked with customers in the cell therapy, molecular, and mRNA spaces.